Xianchu Pharmaceutical: Received Administrative Penalty Decision, Fined 195 million yuan.

Xianju Pharmaceutical announced that on April 30, 2025, the company received an "Administrative Penalty Decision" from the Tianjin Market Supervision Administration, stating that the company, in the form of a monopoly agreement, fixed and changed the price of prednisolone sodium phosphate raw materials with other operators in competitive relations, excluding and restricting competition in the sales of the raw materials. The company was fined a total of 195 million yuan, including the confiscation of illegal proceeds of 23.7467 million yuan and a fine of 171 million yuan, which is 8% of the sales in 2023. The company's main person in charge, Zhang Yusong, was fined 600,000 yuan. The company confirmed that this penalty does not involve a mandatory delisting for major violations, causing some negative impact on the company's current financial statements, but it does not affect normal operation and development. The company has established anti-monopoly compliance management guidelines and employee compliance manuals, conducted comprehensive risk assessments and special training to strengthen anti-monopoly compliance management.